Home
About Us
Introduction
Career Opportunites
Contact Details
Collaborations
News & Resources
News
News Archives
Conferences
Resources
Newsletter Archives
Literature
Case Studies
eBook: Pain processing and Pathways
Whitepapers: Preclinical Efficacy Models
Services
In Vitro Services
In vitro Screening Assays
In vitro Primary Cell assays
Inflammation Disease Models
General models of inflammation
Rheumatoid Arthritis
Allergic Asthma
Contact Dermatitis
Psoriasis
Inflammatory Bowel Disease (IBD)
Senerga Mode of Action Program
Neurology/CNS Models
Multiple Sclerosis in-vivo model
Parkinson's Disease
Gliosis
Pain Models
Nociception Pain Models
Neuropathic Pain Models
Post-operative Pain Models
Inflammatory Pain Models
Ischemia
Myocardial Infarct - IR Injury
Focal Cerebral Ischemia (MCAo)
Global Cerebral Ischemia (4VO)
Kidney IR
White Papers
Capabilities
Preclinical CRO Blog
Contact Us
Contact Us
Products
Biocombinator
Subscribe by Email
Your email:
Posts by Topic
contract research (9)
in vitro compound screening (1)
in vivo efficacy (18)
in vivo pain models (9)
inflammation (14)
Mode of action (2)
Multiple Sclerosis (2)
Myocardial Infarct (2)
Neuroinflammation (10)
neurology (2)
Pain (9)
Parksinson's Disease (1)
Rheumatoid Arthritis (7)
Resources
Whitepapers
eBook: Pain Processing
eBook: Pain & Inflammation
Case Study
Preclinical Drug Discovery Blog
Current Articles
|
RSS Feed
Microglial involvement in Neuropathic Pain: 5 activation pathways
Overview of microglial cells in the CNS
Behavior based findings in preclinical nerve injury models
New eBook: The link b/t pain & inflammation, targets in the overlap?
The ideal preclinical model system: large vs small species.
Receptor & Receptor Ion Channels involved in neuropathic pain.
Preclinical contact hypersensitivity models - DNCB or FITC?
Inflammatory events underlying cardiovascular disease.
Inflammation & Pain processing: Relevant preclinical efficacy models
The link between TH17 & osteoclast function in RA
Anti-inflammatory cytokines as potential targets for neuropathic pain
Adipose tissue - a site of inflammation?
The need for novel asthma treatments & suitable preclinical models.
Pro-inflammatory cytokines as potential targets in neuropathic pain.
T cells in Rheumatoid Arthritis: where, why and when?
Cells involved in the neuro/immune interactions along pain processing pathway.
Case study: 25 preclinical CAIA studies, 18 months, 1 out-licensed compound
Interaction between nervous & immune systems. Preclinical targets.
Inflammatory mediators and neuropathic pain: preclinical models
The link between pain & inflammation - relevant preclinical models?
The EAE model is associated with all Seven FDA Approved MS Drugs
What in vivo models of PD have revealed about pathogenesis and treatment
Cutting edge Readouts for Rheumatoid Arthritis Model (part 2)
Cutting Edge Readouts for Rheumatoid Arthritis Models (part 1)
Preclinical Occlusion-induced ischemia reperfusion injury model
Targeting fibroblast-like synovioctyes: preclinical screening assays.
Effiacy of anti-CD20 therapy in Rhuematoid Arthritis
Determine immunomodulatory mechanism of action for compounds
Parameters for evaluating neuroprotective treatments in EAE models
Why is post-operative pain under treated?
Pain Processing: Cation Channel Blockers. Choosing models of pain.
Cannabinoid System as a target for pain relief.
α2-adrenergic Agonists and Tricyclic Antidepressants Evaluating Compounds in Relevant Models of Pain
Error sending email
Email sent successfully
Email article
Email To :
Email From :
Message :